Product Details
| Product Name:
GSK2334470 |
CAS No.:
1227911-45-6 |
| Purity:
99.87% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | GSK2334470 |
| Description | GSK2334470 is a novel PDK1 inhibitor (IC50: ~10 nM, in a cell-free assay), with no inhibitory at other close related AGC-kinases. |
| Cell Research | GSK2334470 is dissolved in DMSO and diluted with appropriate medium before use. To study the inhibitory effect of GSK2334470 on mTOR-S6K pathway, non-resistant cells and the resistant sublines are treated with GSK2334470 at 5 μM for 1.5 and 12 h in 10 % FBS medium with/without MK-2206 (5 μM)[2]. |
| Kinase Assay | FGFR1-4 Biochemical Assays: FGFR kinase inhibition assays are performed at KM for ATP. Picomolar to low nanomolar concentrations of FGFR proteins are incubated in 1× Kinase Reaction Buffer (KRB) with 1 μM of CSKtide and 50 to 250 of μM ATP at 25°C for 90 minutes in the presence or absence of a dosed concentration series of inhibitor. All reactions are terminated by the addition of Stop buffer, and plates are read on a Caliper EZReader2. IC50 values are fit with a four-parameter log[Inhibitor] versus response model with floating Hill Slope. |
| In vivo | The efficacy of the PDK1 inhibitor (PDKi) GSK2334470 was assessed in newborn BrafV600E::Pten?/? mice through systemic administration of 4-HT. Administering PDK1 twice weekly significantly inhibited pigmented lesions and concurrent melanomagenesis, alongside a notable reduction (~80%) in lung metastases and lymph node metastases, as quantified by H&E staining and S100 immunostaining, respectively. This outcome mirrors the effects observed with the genetic deletion of Pdk1[4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 83 mg/mL (179.4 mM)
DMSO : 83 mg/mL (179.4 mM)
|
| Keywords | GSK-2334470 | Inhibitor | GSK 2334470 | PDK-1 | inhibit | GSK2334470 |
| Inhibitors Related | MP7 | Rabusertib | M77976 | Polyphyllin I | Sodium dichloroacetate | RS1-PDK1 inhibitor | BX795 | Dehydroabiethylamine | Dicoumarol | Osu03012 | PS 48 | PHT-427 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Oxidation-Reduction Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2566715-93-1
$68.00 / 1mg
-
CAS:201530-41-8
$43.00 / 5mg
-
CAS:787-93-9
$29.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States